INNOVATION AND MARKET ACCESS IN ASIA-PACIFIC- WHAT EVIDENCE AND PROCESSES ARE APPROPRIATE FOR REIMBURSEMENT? CHINA, JAPAN, SOUTH KOREA, TAIWAN AND AUSTRALIA COMPARED.
Author(s)
Chee-Jen Chang, PhD, MS, Taiwan Society for Pharmacoeconomics and Outcome Research, Director, Clinical Informatics and Medical Statistics Research Center, and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Tao Yuan, Taiwan; Bruce Crawford, MA, MPH, InVentiv Health Japan G.K., Tokyo, Japan; Mendel Grobler, B.Pharm, MBA, Amgen Inc., North Ryde, NSW, Australia; Shanlian Hu, MS, MD, Shanghai Health Development Research Center, Shanghai, China; Sukyeong Kim, PhD, RPh, MPH, Coordinating Center for National Health Clinical Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)
Presentation Documents
Health technology assessment (HTA) is relatively advanced in the EU, but also developing rapidly in Asia-Pacific. However, the requirements for pharmacoeconomics evidence vary across countries, from well-defined criteria in some countries to not well established or defined in other countries. This forum helps audience to understand new developments and to promote collaboration among different key stakeholders. The forum will provide an overview and case studies of new developments in China, Japan, South Korea, Taiwan and Australia in the following areas: • Is HTA/cost-effectiveness nice-to-have or must have? What are the evidence requirements beyond clinical trials?
• Close collaborations and proactive dialogues across Asia-Pacific countries among key stakeholders
• The utilization of real-world data to support the decision making in the region
• Comparisons of the HTA development between EU and Asia countries will be discussed
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Code
F8
Topic
Health Technology Assessment, Organizational Practices